NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.95 +0.10 (+1.71 %)
(As of 05/23/2018 10:55 AM ET)
Previous Close$5.81
Today's Range$5.80 - $5.95
52-Week Range$3.83 - $7.01
Volume28,160 shs
Average Volume2.47 million shs
Market Capitalization$1.33 billion
P/E Ratio-16.00
Dividend YieldN/A
Beta1.34

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio7.61
Quick Ratio7.51

Price-To-Earnings

Trailing P/E Ratio-16.00
Forward P/E Ratio-15.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 million
Price / Sales76.80
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book11.90

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-483.98%
Return on Equity-66.77%
Return on Assets-60.12%

Miscellaneous

Employees173
Outstanding Shares216,580,000

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) announced its earnings results on Thursday, May, 3rd. The company reported ($0.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The company earned $3.77 million during the quarter, compared to analysts' expectations of $4.18 million. TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. TherapeuticsMD's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) EPS. View TherapeuticsMD's Earnings History.

What price target have analysts set for TXMD?

9 brokers have issued 12-month price objectives for TherapeuticsMD's shares. Their predictions range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.8571 in the next year. View Analyst Ratings for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 57,526,791 shares, an increase of 1.7% from the April 13th total of 58,531,859 shares. Based on an average trading volume of 1,837,473 shares, the days-to-cover ratio is presently 31.3 days. Approximately 33.2% of the shares of the company are sold short.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
  • Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)
  • Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52)

Has TherapeuticsMD been receiving favorable news coverage?

News coverage about TXMD stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a daily sentiment score of -0.19 on Accern's scale. They also assigned press coverage about the company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (9.08%), BlackRock Inc. (6.43%), Franklin Resources Inc. (4.88%), Stifel Financial Corp (0.86%), First Eagle Investment Management LLC (0.81%) and OppenheimerFunds Inc. (0.76%). View Institutional Ownership Trends for TherapeuticsMD.

Which major investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Guggenheim Capital LLC, Teacher Retirement System of Texas, Claraphi Advisory Network LLC and California State Teachers Retirement System. View Insider Buying and Selling for TherapeuticsMD.

Which major investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP, Trellus Management Company LLC, Iridian Asset Management LLC CT, Cubist Systematic Strategies LLC, Schwab Charles Investment Management Inc. and Barclays PLC. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $5.95.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.33 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (TXMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TherapeuticsMD (NASDAQ:TXMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $14.8571, suggesting that the stock has a possible upside of 149.70%. The high price target for TXMD is $28.00 and the low price target for TXMD is $6.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.892.91
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.8571$14.50$14.50$14.7222
Price Target Upside: 149.70% upside184.31% upside189.42% upside130.01% upside

TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History

Price Target History for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018OppenheimerSet Price TargetBuy$10.00HighView Rating Details
3/9/2018Noble FinancialReiterated RatingBuyMediumView Rating Details
1/7/2018Cantor FitzgeraldReiterated RatingBuy$28.00LowView Rating Details
12/20/2017Deutsche BankSet Price TargetBuy$9.00HighView Rating Details
11/6/2017CowenReiterated RatingOutperform$13.00 ➝ $16.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$15.00MediumView Rating Details
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00N/AView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$20.00LowView Rating Details
7/11/2017CIBCUpgradeMarket Perform ➝ OutperformHighView Rating Details
12/6/2016GuggenheimReiterated RatingPositiveN/AView Rating Details
12/4/2016Goldman SachsReiterated RatingBuy$10.50N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

TherapeuticsMD (NASDAQ:TXMD) Earnings History and Estimates Chart

Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.10)($0.08)($0.09)
Q2 20182($0.11)($0.10)($0.11)
Q3 20182($0.12)($0.10)($0.11)
Q4 20182($0.15)($0.09)($0.12)

TherapeuticsMD (NASDAQ TXMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.10)($0.11)$4.18 million$3.77 millionViewN/AView Earnings Details
2/20/2018Q4 2017($0.09)($0.10)$4.66 million$4.13 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.10)($0.0710)$5.36 million$4.42 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.11)($0.10)$4.91 million$4.25 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.11)($0.11)$5.29 million$3.99 millionViewN/AView Earnings Details
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)$4.34 million$4.48 millionViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)$3.90 million$4.19 millionViewN/AView Earnings Details
8/6/2014Q2 2014($0.08)($0.07)$3.12 million$3.75 millionViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
11/4/2013Q3 2013($0.04)($0.06)$2.55 million$2.30 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.06)($0.05)$1.51 million$2.08 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.06)($0.05)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.04)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

TherapeuticsMD (NASDAQ:TXMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.85%
Institutional Ownership Percentage: 72.70%
Insider Trading History for TherapeuticsMD (NASDAQ:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ TXMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2017Tommy G ThompsonDirectorBuy5,000$6.21$31,050.003,555View SEC Filing  
8/30/2017Tommy G ThompsonDirectorBuy5,000$5.99$29,950.003,555View SEC Filing  
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.0036,000View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.0048,500View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.0010,000View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60297,000View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.401,722,419View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.1021,029,533View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.006,318,018View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.0022,011,586View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.006,343,018View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TherapeuticsMD (NASDAQ TXMD) News Headlines

Source:
DateHeadline
$4.13 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter$4.13 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 21 at 4:22 AM
 Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Announce -$0.12 Earnings Per Share Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - May 19 at 9:25 AM
TherapeuticsMD Announces Investor and Analyst Day on June 4TherapeuticsMD Announces Investor and Analyst Day on June 4
finance.yahoo.com - May 16 at 5:40 PM
TikaMobile Selected by TherapeuticsMD as Business Intelligence Platform ProviderTikaMobile Selected by TherapeuticsMD as Business Intelligence Platform Provider
globenewswire.com - May 16 at 8:20 AM
TherapeuticsMD Sees Unusually Large Options Volume (TXMD)TherapeuticsMD Sees Unusually Large Options Volume (TXMD)
www.americanbankingnews.com - May 16 at 6:46 AM
TherapeuticsMD (TXMD) Upgraded at Zacks Investment ResearchTherapeuticsMD (TXMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:51 PM
TherapeuticsMD (TXMD) Lifted to "Buy" at ValuEngineTherapeuticsMD (TXMD) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
FY2020 EPS Estimates for TherapeuticsMD Inc Lowered by Oppenheimer (TXMD)FY2020 EPS Estimates for TherapeuticsMD Inc Lowered by Oppenheimer (TXMD)
www.americanbankingnews.com - May 7 at 5:17 AM
TherapeuticsMDs (TXMD) CEO Robert Finizio on Q1 2018 Results - Earnings Call TranscriptTherapeuticsMD's (TXMD) CEO Robert Finizio on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 8:28 AM
Oppenheimer Reiterates $10.00 Price Target for TherapeuticsMD (TXMD)Oppenheimer Reiterates $10.00 Price Target for TherapeuticsMD (TXMD)
www.americanbankingnews.com - May 4 at 10:31 PM
Edited Transcript of TXMD earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of TXMD earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 5:32 PM
TherapeuticsMD (TXMD) Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPSTherapeuticsMD (TXMD) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 4 at 3:32 PM
TherapeuticsMD: 1Q Earnings SnapshotTherapeuticsMD: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:19 AM
BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11
www.reuters.com - May 3 at 5:23 PM
TherapeuticsMD Announces First Quarter 2018 Financial ResultsTherapeuticsMD Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:23 PM
$4.10 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter$4.10 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 3 at 2:30 AM
TherapeuticsMD (TXMD) Rating Increased to Hold at ValuEngineTherapeuticsMD (TXMD) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM
Zacks: Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Post -$0.10 EPSZacks: Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Post -$0.10 EPS
www.americanbankingnews.com - May 1 at 7:14 PM
TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
finance.yahoo.com - May 1 at 5:17 PM
Drug Makers Stocks Research Reports Released on Sanofi, Shire, TherapeuticsMD, and ZogenixDrug Makers Stocks' Research Reports Released on Sanofi, Shire, TherapeuticsMD, and Zogenix
www.prnewswire.com - April 26 at 8:18 AM
TherapeuticsMD (TXMD) Downgraded by Zacks Investment ResearchTherapeuticsMD (TXMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 2:58 PM
TherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment ResearchTherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 2:28 PM
 Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million
www.americanbankingnews.com - April 16 at 2:19 AM
TherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per ShareTherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 14 at 7:18 PM
BRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HRBRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HR
www.reuters.com - April 13 at 8:20 AM
TherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment ResearchTherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:23 PM
TherapeuticsMD Enters Into Label Negotiations for TX-004HRTherapeuticsMD Enters Into Label Negotiations for TX-004HR
finance.yahoo.com - April 11 at 8:32 AM
TherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche BankTherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche Bank
www.americanbankingnews.com - April 9 at 10:52 PM
TherapeuticsMD (TXMD) PT Set at $10.00 by OppenheimerTherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer
www.americanbankingnews.com - April 6 at 10:22 PM
TherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClubTherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 6:21 PM
TherapeuticsMD (TXMD) Upgraded at ValuEngineTherapeuticsMD (TXMD) Upgraded at ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM
TherapeuticsMD Announces Expansion of Board of DirectorsTherapeuticsMD Announces Expansion of Board of Directors
finance.yahoo.com - April 2 at 8:41 AM
TherapeuticsMD (TXMD) Upgraded to Sell by BidaskClubTherapeuticsMD (TXMD) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - March 30 at 10:02 PM
TherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 MillionTherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 Million
www.americanbankingnews.com - March 30 at 1:52 AM
TherapeuticsMD (TXMD) Receives Buy Rating from OppenheimerTherapeuticsMD (TXMD) Receives Buy Rating from Oppenheimer
www.americanbankingnews.com - March 21 at 7:48 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and ZogenixQuotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix
www.bizjournals.com - March 19 at 5:17 PM
TherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA DateTherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA Date
finance.yahoo.com - March 19 at 8:24 AM
TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from BrokeragesTherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 3:42 AM
 Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS
www.americanbankingnews.com - March 11 at 2:12 PM
TherapeuticsMD Inc (TXMD) Short Interest UpdateTherapeuticsMD Inc (TXMD) Short Interest Update
www.americanbankingnews.com - March 11 at 1:58 AM
The 5 Most Shorted Nasdaq StocksThe 5 Most Shorted Nasdaq Stocks
www.msn.com - March 10 at 6:23 PM
TherapeuticsMD (TXMD) Given "Buy" Rating at Noble FinancialTherapeuticsMD (TXMD) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - March 10 at 5:09 PM
Therapeutics Wins FDA Nod, Stocks Dont BudgeTherapeutics Wins FDA Nod, Stocks Don't Budge
www.baystreet.ca - March 9 at 6:49 PM
TherapeuticsMD (TXMD) Given a $10.00 Price Target at OppenheimerTherapeuticsMD (TXMD) Given a $10.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 9 at 2:44 PM
TherapeuticsMD (TXMD) FDA Accepts TX-001HR NDA; 10/28/18 ... - StreetInsider.comTherapeuticsMD (TXMD) FDA Accepts TX-001HR NDA; 10/28/18 ... - StreetInsider.com
www.streetinsider.com - March 9 at 8:21 AM
Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMDToday’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMD
finance.yahoo.com - March 9 at 8:21 AM
BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001HrBRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr
www.reuters.com - March 8 at 6:41 PM
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HRTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
finance.yahoo.com - March 8 at 6:41 PM
TherapeuticsMD to Present at Two Upcoming Investor Conferences ... - Business Wire (press release)TherapeuticsMD to Present at Two Upcoming Investor Conferences ... - Business Wire (press release)
www.businesswire.com - March 7 at 8:19 AM
Commit To Purchase TherapeuticsMD At $3, Earn 17.2% Annualized Using Options - NasdaqCommit To Purchase TherapeuticsMD At $3, Earn 17.2% Annualized Using Options - Nasdaq
www.nasdaq.com - March 7 at 8:19 AM

SEC Filings

TherapeuticsMD (NASDAQ:TXMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TherapeuticsMD (NASDAQ TXMD) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.